The company along with Enzene Bioscience entered into share subscription and shareholder agreement. Sunsure Solarpark is a wholly owned subsidiary of Sunsure Energy is engaged in the business of generation, production and distribution of electricity from renewable energy sources. The companies will acquire 26% stake in Sunsure Solarpark for total consideration of Rs 1.95 crore to purchase renewable power source in compliance with the environmental social governance thereby resulting in reduced power/ electricity costs. In order to comply with regulatory requirement, the company and Enzene shall, being the captive users, collectively hold not less than 26% stake in the equity share capital of Sunsure Solarpark on a fully diluted basis and consume the solar energy generated therefrom, throughout the term of Share Subscription and Shareholder's Agreement and certain other transaction documents. Total contribution for the acquisition of equity share capital of Sunsure Solarpark will be Rs 1.95 crore, with Alkem Laboratories contributing Rs 93.60 lakh while Enzene Bioscience contributing Rs 1.01 crore. Alkem will hold 26% stake in Sunsure Solarpark while Enzene Bioscience will hold a 13.52% stake. The said transaction will be completed by the end of April 2025. Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25.Powered by Capital Market - Live

The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India. The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5721.55, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Alkem Laboratories Ltd has dropped around 1.32% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 82592 shares today, compared to the daily average of 5.98 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 5751.2, up 1.67% on the day. Alkem Laboratories Ltd is up 24.03% in last one year as compared to a 16.91% spurt in NIFTY and a 38.53% spurt in the Nifty Pharma index.The PE of the stock is 31.19 based on TTM earnings ending September 24.Powered by Capital Market - Live

Net profit of Alkem Laboratories rose 10.98% to Rs 688.64 crore in the quarter ended September 2024 as against Rs 620.52 crore during the previous quarter ended September 2023. Sales declined 0.74% to Rs 3414.67 crore in the quarter ended September 2024 as against Rs 3440.17 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3414.673440.17 -1 OPM %22.0521.71 - PBDT859.17779.60 10 PBT780.26705.70 11 NP688.64620.52 11 Powered by Capital Market - Live

Alkem Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 5383.3, down 2.18% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Alkem Laboratories Ltd has eased around 13.89% in last one month.Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 1.8 lakh shares today, compared to the daily average of 1.92 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 5426, down 1.11% on the day. Alkem Laboratories Ltd jumped 23.9% in last one year as compared to a 20.25% rally in NIFTY and a 40.48% spurt in the Nifty Pharma index.The PE of the stock is 31.15 based on TTM earnings ending June 24.Powered by Capital Market - Live

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate 'SON-080' for the treatment of diabetic peripheral neuropathy in India. 'SON-080' is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.Powered by Capital Market - Live

SON-080 is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India. According to company, 'SON-080' has undergone many years of development and the previous clinical trials have generated safety data from over 200 patients. 'SON-080' has demonstrated compelling preclinical efficacy data in both diabetic peripheral neuropathy and chemotherapy induced neuropathy, including the ability to prevent the development of neuropathy and reverse established neuropathy when assessed by nerve conduction, histological integrity and sensorimotor function measurements. Dr. Akhilesh Sharma, president & chief medical officer of Alkem said, 'We are pleased to partner with Sonnet for this programme. We believe 'SON-080' is a unique asset that has demonstrated promising disease modifying potential for diabetic peripheral neuropathy with translational studies showing nerve regeneration. There is a large prevalence of diabetic peripheral neuropathy in India, which we believe underscores the need for the drug development in this territory and potential value.' Pankaj Mohan, founder & chief executive officer of Sonnet, said, 'We are excited to partner with Alkem and look forward to advancing 'SON-080' into phase 2 clinical development. We believe that Alkem is the ideal partner with significant experience and expertise.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company reported 90.13% jump in consolidated net profit to Rs 545.16 crore on 2.16% rise in revenue from operations to Rs 3,031.82 crore in Q1 FY25 over Q1 FY24. Shares of Alkem Laboratories slipped 3.17% to currently trade at Rs 6,090.55 on the BSE.Powered by Capital Market - Live

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6295, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Alkem Laboratories Ltd has risen around 18.26% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 2.52 lakh shares today, compared to the daily average of 3.65 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6309.05, up 1.17% on the day. Alkem Laboratories Ltd is up 72.23% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 35.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 6174.95, up 2.93% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Alkem Laboratories Ltd has gained around 16.3% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has gained around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 2.31 lakh shares today, compared to the daily average of 3.57 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6198, up 2.63% on the day. Alkem Laboratories Ltd is up 69.51% in last one year as compared to a 31.09% jump in NIFTY and a 54% jump in the Nifty Pharma index.The PE of the stock is 33.97 based on TTM earnings ending June 24.Powered by Capital Market - Live